Several surface antigens in NSCLC such as epidermal growth factor receptor (EGFR), carcinoembryonic antigen (CEA), human epidermal growth factor receptor 2 (HER2), mesothelin (MSLN), disialoganglioside (GD2), receptor tyrosine kinase-like orphan receptor 1 (ROR1), mucin 1 (MUC1), glypican-3 (GPC3), delta-like ligand 3 (DLL3), and PD-L1 are currently under investigation for CAR-T therapeutics (Table 2). This evidence concerns the gene MSLN and non-small cell lung carcinoma.